Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Breast Neoplasms 14Sarcoma 11Glioblastoma 11Squamous Cell Carcinoma of Head and Neck 10Esophageal Neoplasms 9Rectal Neoplasms 8Stomach Neoplasms 7Urinary Bladder Neoplasms 6Neoplasms 6Carcinoma, Hepatocellular 6Pancreatic Neoplasms 5Colorectal Neoplasms 5Brain Neoplasms 5Oropharyngeal Neoplasms 4Lung Neoplasms 4Hypopharyngeal Neoplasms 4Head and Neck Neoplasms 4Glioma 4Colonic Neoplasms 4Recurrence 3Prostatic Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasm Metastasis 3Mouth Neoplasms 3Melanoma 3Astrocytoma 3Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Skin Neoplasms 2

Interventions

endostar protein 1Surgical Procedures, Operative 1Endostatins 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unresectable Non-small Cell Lung Cancer × Surgical Procedures, Operative × 1 year × Clear all
NCT06617936 2025-07-15

Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

Shandong Public Health Clinical Center

Phase 2 Recruiting
36 enrolled
Thoracic

Unresectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡